

## Conflict of interest

The authors have no conflicts of interest to declare.

## Acknowledgements

None.

## References

1. Bintlcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. *Eur Respir Rev*. 2016;25:303–16.
2. Walker SP, Morley AJ, Staddon L, De Fonseka D, Arnold DT, Medford ARL, et al. Nonmalignant pleural effusions: a prospective study of 356 consecutive unselected patients. *Chest*. 2017;151:1099–105.
3. DeBiasi EM, Pisani MA, Murphy TE, Araujo K, Kookoolis A, Argento AC, et al. Mortality among patients with pleural effusion undergoing thoracentesis. *Eur Respir J*. 2015;46:495–502.
4. Bakirci T, Sasak G, Ozturk S, Akcay S, Sezer S, Haberal M. Pleural effusion in long-term hemodialysis patients. *Transpl Proc*. 2007;39:889–91.
5. Kwan BC, Chow KM, Pang WF, Leung CB, Li PK, Szeto CC. Unexplained exudative pleural effusion in chronic peritoneal dialysis patients. *Perit Dial Int*. 2010;30:534–40.
6. Ray S, Mukherjee S, Ganguly J, Abhishek K, Mitras S, Kundu S. A cross-sectional prospective study of pleural effusion among cases of chronic kidney disease. *Indian J Chest Dis Allied Sci*. 2013;55:209–13.
7. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis*. 2009;53:982–92.

S. Hamada<sup>a,\*</sup>, T. Sano<sup>b</sup>, Y. Nagatani<sup>b</sup>, M. Tsukino<sup>a</sup>

<sup>a</sup> Department of Respiratory Medicine, Hikone Municipal Hospital, 1882, Hassakacho, Hikone 522-8539, Japan

<sup>b</sup> Department of Urology, Hikone Municipal Hospital, 1882, Hassakacho, Hikone 522-8539, Japan

\* Corresponding author.

E-mail address: sh1124@kuhp.kyoto-u.ac.jp (S. Hamada).

<https://doi.org/10.1016/j.pulmoe.2018.10.007>  
2531-0437/

© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Cystic fibrosis – How we reach adult life



### Fibrose Quística – Como chegamos à idade adulta

Until recently, cystic fibrosis (CF) was considered a paediatric disease, and transition of patients to adult care was rarely performed due to low life expectancy and reduced experience from adult Medicine in the follow-up of this disease. Nowadays, due to significant improvement of CF survival rates, almost all of these patients reach adulthood.<sup>1,2</sup> The transference of teenagers with a chronic disease like CF to adult care is a very stressful phase, sometimes faced with some anxiety by both parents and patients. Therefore, a transition period is fundamental for both, with the aim of promoting the patient's autonomy and acceptance of new roles, but also giving continuity of care. In the Specialized Centre of Cystic Fibrosis (SCCF) of the Hospital Santa Maria (Lisbon), this transition happens over three appointments, where both paediatric and adult physicians are present. Since the implementation of this programme in 2000, 54 young adults have been transferred to adult care.

The aim of this study was to characterize the clinical status of CF patients during the year of transition to adult care in a 7-year period.

We conducted a retrospective, descriptive study of all patients transferred to adult care between January 2010 and December 2016. Clinical records were reviewed and the following data were obtained: sex, age at diagnosis, genotype, treatment performed, complications, airway bacterial colonization, lung function (forced expiratory volume in 1s

(FEV<sub>1</sub>)) and nutritional status (body mass index – BMI) in the year of transition. IBM SPSS v21.0<sup>®</sup> and Microsoft Excel 2013<sup>®</sup> were used for the descriptive analysis.

From a total of 87 patients followed at the SCCF during the study period, 25 had reached adult age, of which 19 were transferred to adult Pulmonology. The main reasons for delay in transfer to adult care were either clinical instability or personal reasons (e.g. waiting for placement in University in another city). Nine (47%) patients were male, median age at diagnosis was 2.8 years [minimum 34 days; maximum 14 years] and 9 were homozygous for F508del mutation. Most patients (79%, *n* = 15) presented exocrine pancreatic insufficiency, six (32%) had liver disease, two (11%) CF-related diabetes and four (21%) had only pulmonary manifestations (Table 1). All patients were transferred to adult care up to the age of 21 years, the majority (63%, *n* = 12) at 18 years.

Regarding pulmonary function, six (32%) patients presented FEV<sub>1</sub> < 70%, of which only 1 had severe obstruction (FEV<sub>1</sub> < 40%) (Table 1).

Concerning nutritional status, three patients (16%) had a BMI < 18 kg/m<sup>2</sup>.


As for airway bacterial colonization, the most common microorganisms isolated during the year of transition were *Staphylococcus aureus* (*n* = 12) and *Pseudomonas aeruginosa* (*n* = 11) (Fig. 1), which were responsible for chronic colonization in 57.9% and 31.6% of patients, respectively.

In terms of treatment, 13 (68%) patients had inhaled antibiotics, 16 (84%) dornase alfa and 16 (84%) pancreatic enzymes. No patients were on home oxygen therapy.

With improvements in healthcare in the last decades, nowadays 85% of chronic paediatric patients reach adulthood,<sup>3</sup> highlighting the importance of continued care and transition programmes to adult Medicine. Understand-

**Table 1** Sample characterization ( $n=19$ ). CF = cystic fibrosis.

Male gender, $n$ (%)	9 (47)
Age at diagnosis, median (min; max)	2.8 years (34 days; 14 years)
Age at transition to adult care, $n$ (%)	
17 years	2 (10.5)
18 years	12 (63.2)
19 years	3 (15.8)
20 years	1 (5.3)
21 years	1 (5.3)
Genotype, $n$ (%)	
F508del/F508del	9 (47)
F508del/R334W	3 (16)
3272-26A-G/3007delG	1 (5)
A561E/A561E	1 (5)
F508del/R1066C	1 (5)
F508del/51235R-IVS8-6(5t)	1 (5)
R334W/smi	1 (5)
Complications, $n$ (%)	
Exocrine pancreatic insufficiency	15 (79)
Liver disease	6 (32)
CF-related diabetes	2 (11)
Only pulmonary manifestations	4 (21)
Pulmonary function, $n$ (%)	
FEV1 < 40%	1 (5)
FEV1 40–69%	6 (32)
FEV1 >70%	12 (63)

**Figure 1** Bacterial colonization in the year of transition to adult care ( $n=19$ ).

ing the clinical condition in which patients reach adulthood is of utmost importance, as an audit of paediatric clinical care and for future comparison of outcomes.

In CF patients, not only has life expectancy increased, but nutritional status and quality of life have also improved, which are known to correlate to better respiratory function.<sup>6</sup>

To our knowledge, this is the first study published in Portugal to describe this reality.

We hope these results can be used for future comparison and evaluation of outcome improvements in CF patients, namely the ones who were lately diagnosed through the neonatal screening programme, most of which began follow-up and treatment even before onset of symptoms. We hypothesize that they will have better nutritional status and pulmonary function at transition to adult care, as has been previously reported.<sup>4–6</sup>

## Conflicts of interest

The authors have no conflicts of interest to declare.

## References

- Zolin A, Rens J, Fox A, Iansa P, Gulmans V, Jung A, et al. ECFSPR annual report 2015. Karup: Cystic Fibrosis Foundation; 2017.
- Tuchman L, Schwartz L, Sawicki G, Britto M. Cystic fibrosis and transition to adult medical care. *Pediatrics*. 2010;125:566–73.
- Reid G, Irvine M, McCrindle B, Sananes R, Ritvo P, Siu S, et al. Prevalence and correlates of successful transfer from pediatric to adult health care among a cohort of young adults with complex congenital heart defects. *Pediatrics*. 2004;113:197–205.
- Milla C. Association of nutritional status and pulmonary function in children with cystic fibrosis. *Curr Opin Pulm Med*. 2004;10:505–9.
- Milla C. Nutrition and lung disease in cystic fibrosis. *Clin Chest Med*. 2007;28:319–30.
- Cystic Fibrosis Trust – Nutrition Working Group. Nutritional management of cystic fibrosis. London: Cystic Fibrosis Trust; 2016.

I. Serras<sup>a,\*</sup>, J.A. Oliveira<sup>b</sup>, L. Pereira<sup>b,c</sup>, C. Barreto<sup>b,c</sup>

<sup>a</sup> *Serviço de Pediatria, Centro Hospitalar Universitário do Algarve, Unidade de Portimão, Estrada do Poço Seco, 8500-338 Portimão, Portugal*

<sup>b</sup> *Departamento de Pediatria, Hospital de Santa Maria (CHLN), Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal*

<sup>c</sup> *Centro Especializado de Fibrose Quística, Hospital de Santa Maria (CHLN), Centro Académico de Medicina de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal*

\*Corresponding author.

E-mail address: [inesserraped@gmail.com](mailto:inesserraped@gmail.com) (I. Serras).

<https://doi.org/10.1016/j.pulmoe.2019.02.001>  
2531-0437/

© 2019 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).